Pristiq Extended-Release contains desvenlafaxine for adult major depressive disorder. The tablet's release system, blood-pressure monitoring and a planned reduction when stopping are practical features of this medicine.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | desvenlafaxine succinate (strengths expressed as desvenlafaxine) |
| Medicine class | Serotonin and norepinephrine reuptake inhibitor (SNRI) |
| Forms and strengths | Extended-release oral tablets: 25, 50 and 100 mg |
An adult depression indication
Pristiq is an SNRI labeled for major depressive disorder in adults. It is not approved for pediatric patients in the cited US prescribing information. Related antidepressants may have different indications; those uses should not be transferred to desvenlafaxine simply because they share a class.
Source: [1]
Preserve the extended-release tablet
The available labeled strengths are 25, 50 and 100 mg of desvenlafaxine. Tablets must be swallowed whole with fluid, rather than divided, crushed, chewed or dissolved. Kidney function can substantially change prescribing. The listed strengths do not identify which regimen is appropriate for an individual.
Source: [1]
Blood pressure and mood follow-up
Control hypertension before starting and monitor blood pressure regularly. The boxed warning describes increased suicidal thoughts and behaviors in children, adolescents and young adults taking antidepressants, and calls for close monitoring. Report worsening mood promptly; immediate danger needs emergency assistance. Screen for bipolar disorder before treatment.
Source: [1]
Important reactions and medicine combinations
Serotonin syndrome, increased bleeding, low sodium, mania and sexual dysfunction are among the labeled risks. MAO inhibitors are contraindicated within specified separation intervals. Prescribers also need to know about venlafaxine allergy, other serotonergic drugs, anticoagulants and NSAIDs. New severe symptoms need assessment rather than an unsupervised dose adjustment.
Source: [1]
A reduction plan belongs to the prescription
Discontinuation symptoms can occur when Pristiq is reduced or stopped. The label recommends gradual reduction whenever possible, with an individualized plan. Desvenlafaxine and venlafaxine are distinct medicines: similar names or a pharmacological relationship do not establish a milligram-for-milligram substitution.
Further reading includes the Pristiq and Effexor XR comparison. Its selected comparison facts do not provide a switching or dose-conversion plan.
Source: [1]
Questions and answers
Can a Pristiq tablet be split to reduce the dose?
No. The extended-release tablet must be taken whole; the prescriber needs to plan any reduction using suitable prescribed strengths.
Does the Pristiq label include pediatric depression?
No. The cited US label is for major depressive disorder in adults and does not approve pediatric use.
Is desvenlafaxine the same prescription as venlafaxine?
No. They are distinct active medicines. A clinician must plan any transition between them.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026